Cardiovascular Drugs Global Market Report 2018 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Cardiovascular Drugs Global Market Report 2018

Description:

The global cardiovascular drugs market was valued at around $129 billion in 2017. North America was the largest region in the cardiovascular drugs market in 2017, accounting for nearly 40% market share. Read report – PowerPoint PPT presentation

Number of Views:7

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Cardiovascular Drugs Global Market Report 2018


1
Ca?dioasÐula? D?ugs Glodal Ma?ket Repo?t ???8
Including AYti-hype?teYsie D?ugs Othe? D?ugs
Fo? Ca?dioasÐula? Diseases HypolipidewiÐs AYti
Th?owdotiÐs
Covering Me?Ðk Co., SaYofi S.A, Pfize? IYÐ.,
B?istol-Mye?s S?uidd CowpaYy, Noa?tis AG
Fed ???8
2
  • Reasons to Purchase
  • Outperform competitors using accurate up to date
    demand-side dynamics information.
  • Identify growth segments for investment.
  • Facilitate decision making on the basis of
    historic and forecast data and the drivers and
    restraints on the market.
  • Create regional and country strategies on the
    basis of local data and analysis.
  • Stay abreast of the latest customer and market
    research findings
  • Benchmark performance against key competitors.
  • Develop strategies based on likely future
    developments.
  • Utilize the relationships between key data sets
    for superior strategizing.
  • Suitable for supporting your internal and
    external presentations with reliable high quality
    data and analysis
  • Gain a global perspective on the development of
    the market.
  • Report will be updated with the latest data and
    delivered to you within 3-5 working days of
    order.
  • Scope
  • Markets Covered Anti-hypertensive Drugs Other
    Drugs For Cardiovascular Diseases
  • Hypolipidemics Anti Thrombotics.
  • Companies Mentioned Merck Co., Sanofi S.A,
    Pfizer Inc., Bristol-Myers Squibb Company,
    Novartis AG
  • Countries Brazil, China, France, Germany, India,
    Italy, Japan, Spain, Russia, UK, USA and
    Australia.

3
Cardiovascular Drugs Market Characteristics
  • Cardiovascular drugs market covers the drugs used
    to treat conditions that affect the heart or
    blood vessels. These conditions include heart
    stroke, coronary artery diseases, valvular
    diseases, peripheral venous diseases,
    pericarditis, endocarditis, cardiac tumors,
    arteriosclerosis, and lymphatic diseases.
    Some of the major cardiovascular drugs
    include anti-hypertensive drugs such as
    calcium channel blockers and Angiotensin II
    receptor antagonists, and hypolipidemic drugs
    such as fibric acid derivatives and bile acid
    binding resins.
  • The market numbers within this briefing are
    restricted to pharmaceutical (drug) treatments
    and do not cover biologic treatments for these
    conditions which are included in a separate
    briefing.
  • The cardiovascular drugs industry is further
    classified as follows
  • Anti-Hypertensive Drugs are used to
  • Hypolipidemic Drugs are those drugs that lower
    lipid and
  • Antithrombotics Drugs are used to prevent and
  • Other (Congestive Heart Failure, Antiarrhythmic
    and Antianginal) Drugs are the drugs that prevent
    congestive heart failure, drugs used for

In this report market value is defined as the
revenues organizations earn by selling their
goods and services within the specified market,
based on the price at which they sell. Only
goods and services traded between entities are
included.
4
The revenues for a specified geography are
consumption values that is, they are revenues
generated by organizations in the specified
geography within the specified market,
irrespective of where they are produced.
5
Cardiovascular Drugs Market Historic Growth
The global cardiovascular drugs market grew from
X billion in 2013 to X billion in 2017 at a
compound annual growth rate (CAGR) of X. The
chart and table below shows the
year-on-year growth of the global
cardiovascular drugs market during 2013 2017.
Drivers of the Market Restraints on the Market
6
Cardiovascular Drugs Market Forecast Growth
The global cardiovascular drugs market is
expected to grow from XX billion in 2017 to
141.4 billion in 2021 at a compound annual
growth rate (CAGR) of XX. The forecasted growth
in this market can be attributed to the
increase in aging population, increase in the
prevalence of cardiovascular diseases and
availability of more generic drugs that reduce
the cost of treatment. The chart and table
below shows the year-on-year growth
of the global cardiovascular drugs market
during 2017 - 2021.
Drivers of the Market Restraints on the Market
7
Cardiovascular Drugs Market Segmentation
The chart and table below shows the split of the
cardiovascular drugs market in 2017.
The total market value for cardiovascular drugs
was X billion in 2017. The markets that are
covered include Anti-hypertensive Drugs Other
Drugs For Cardiovascular Diseases
Hypolipidemics Anti Thrombotics. Anti-hypertensi
ve Drugs was the X largest segment in the
cardiovascular drugs market with X share of
the market. The market value for the
anti-hypertensive drugs was X billion in
2017. Other Drugs For Cardiovascular Diseases
made up around X share of the market. The market
value for the other drugs for cardiovascular
diseases was X billion in 2017.
8
Cardiovascular Drugs Market Regional And Country
Analysis
The Asia Pacific was the largest region in the
cardiovascular drugs market in 2017,
cardiovascular drugs for X billion or X market
share. North America was the x largest region
cardiovascular drugs for X billion or X market
share. Western Europe was the x largest region
cardiovascular drugs for X billion or X market
share.
9
Cardiovascular Drugs Market Competitive Landscape
The leading competitors in the global
cardiovascular drugs market are Merck Co.,
Sanofi S.A, Pfizer Inc., Bristol-Myers Squibb
Company, Novartis AG. The chart and table below
displays the percentage market share of the top
players in the cardiovascular drugs market
industry.
Merck Co. generated revenues of XX billion for
the financial year 2016, an XX increase from the
previous year. Sanofi S.A. generated revenues
of XX billion for the financial year 2016, an
XX decrease from the previous year. Pfizer
Inc. generated revenues of XX billion for the
financial year 2016, an XX increase from the
previous year.
10
Bristol-Myers Squibb Company generated revenues
of XX billion for the financial year 2016, an
XX increase from the previous year. Novartis
AG generated revenues of XX billion for the
financial year 2016, an XX decrease from the
previous year. Eli Lilly And Company generated
revenues of XX billion for the financial year
2016, an XX increase from the previous
year. Johnson Johnson generated revenues of
XX billion for the financial year 2016, an XX
decrease from the previous year. AstraZeneca
Plc. generated revenues of XX billion for the
financial year 2016, an XX decrease from the
previous year. Abbott Laboratories Inc.
generated revenues of XX billion for the
financial year 2016, an XX increase from the
previous year. Bayer AG generated revenues of
XX billion for the financial year 2016, an XX
increase from the previous year. Company
Profile Merck Co. Overview Merck Co. was
the largest company in the cardiovascular drugs
market with a XX share of the market in 2017.
The company was founded in 1891 and is
headquartered in New Jersey, USA. It offers
therapeutic and
11
preventive health solutions through
prescription medicines, vaccines, biologic
therapies and animal health products. Merck
Co. serves drug wholesalers and retailers,
hospitals, government agencies and entities,
physicians, physician distributors,
veterinarians, distributors, animal
producers, and managed health care
providers. Products and Services Merck Co.
operates through following divisions The
Pharmaceutical division offers The Animal Health
division is involved in The Healthcare Services
division offers Strategy Me?Ðk Co.s g?o?th
st?ategy is to eYhaYÐe its glodal
Ða?dioasÐula? business by expanding its research
facilities. In January 2017, the company started
the construction of its new research facility in
South San Francisco which is expected to be ready
by 2019. This facility is expected to have nine
stories and 290,000 square feet of research and
office space that will be used for research
on Financial Performance Me?Ðks P?iwa?y Ca?e
aYd WoweY's Health seÐtioY iY
Pha?waÐeutiÐal division, involved in
cardiovascular drugs manufacturing,
generated revenues of XX billion for the
financial year 2016, a XX decrease from the
previous year. The company had a market Sanofi
S.A Overview Products and Services
Strategy Financial Performance
12
Pfizer Inc. Overview Products and Services
Strategy Financial Performance Bristol-Myers
Squibb Company Overview Products and Services
Strategy Financial Performance Novartis
AG Overview Products and Services
Strategy Financial Performance
About PowerShow.com